Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4791757 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNAGAACYP1A2MAPT | |
| SCHEMBL30374884 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNAGAACYP1A2MAPT | |
| SCHEMBL8873180 | 0.78 | CA12 (0.56) | ALDH1A1LMNAGAAMAPTHPGD | |
| SCHEMBL13024464 | 0.78 | LMNA (0.60) | ALDH1A1LMNAGAACYP1A2MAPT | |
| SCHEMBL19032120 | 0.78 | LMNA (0.60) | ALDH1A1LMNAGAACYP1A2MAPT | |
| SCHEMBL3740247 | 0.78 | ALDH1A1 (0.76) | ALDH1A1LMNAGAACYP1A2MAPT | |
| SCHEMBL9387738 | 0.78 | DAO (0.65) | ALDH1A1LMNAKIF11KDM4EMEN1 | |
| SCHEMBL9180711 | 0.78 | LMNA (0.49) | ALDH1A1LMNAMAPTHPGDADORA1 | |
| SCHEMBL527043 | 0.78 | CYP1A2 (1.00) | ALDH1A1LMNAGAACYP1A2MAPT | |
| SCHEMBL19032063 | 0.77 | MAPT (1.00) | ALDH1A1LMNAGAACYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964944-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | THE UNIVERSITY OF CHICAGO (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230140413-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | THE UNIVERSITY OF CHICAGO | 2023-05-04 | — | — | US | disclosed |
| US-20230140413-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | THE UNIVERSITY OF CHICAGO | 2023-05-04 | — | — | US | disclosed |
| US-20230140413-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | THE UNIVERSITY OF CHICAGO | 2023-05-04 | — | — | US | disclosed |
| US-11414385-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | THE UNIVERSITY OF CHICAGO | 2022-08-16 | — | — | US | disclosed |
| US-20200283391-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | THE UNIVERSITY OF CHICAGO | 2020-09-10 | — | — | US | disclosed |
| US-20200283391-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | THE UNIVERSITY OF CHICAGO | 2020-09-10 | — | — | US | disclosed |
| EP-3394032-A1 | COMPOUNDS AND METHODS FOR TREATING, DETECTING, AND IDENTIFYING COMPOUNDS TO TREAT APICOMPLEXAN PARASITIC DISEASES | The University of Chicago (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112678-A1 | COMPOUNDS AND METHODS FOR TREATING, DETECTING, AND IDENTIFYING COMPOUNDS TO TREAT APICOMPLEXAN PARASITIC DISEASES | MCLEOD RIMA (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112678-A1 | COMPOUNDS AND METHODS FOR TREATING, DETECTING, AND IDENTIFYING COMPOUNDS TO TREAT APICOMPLEXAN PARASITIC DISEASES | MCLEOD RIMA (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2015017589-A1 | 1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283391-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | TUBB1, MYADM, TUBB | ALDH1A1 342/4885LMNA 3310/4885GAA 3214/4885 |
| US-11964944-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | TUBB1, MYADM, TUBB | ALDH1A1 304/4885LMNA 3064/4885GAA 2895/4885 |
| US-20230140413-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | TUBB1, MYADM, TUBB | ALDH1A1 304/4885LMNA 3064/4885GAA 2895/4885 |
| US-11414385-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | TUBB1, MYADM, TUBB | ALDH1A1 342/4885LMNA 3310/4885GAA 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.